Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Onbrez® Breezhaler®
( indacaterol )Respiratory -
NETSPOT®
( gallium Ga 68 dotatate injection )Advanced Accelerator ApplicationsAvailable in -
Neoral®/Sandimmune®
( cyclosporine, USP Modified )Immunology and Dermatology -
Myfortic®
( mycophenolic acid (as mycophenolate sodium) )Immunology and Dermatology -
Mekinist®
( trametinib )Oncology -
Mayzent®
( siponimod )Neuroscience -
Luxturna®
( voretigene neparvovec )OphthalmologyAvailable in